HEAL-LAA Clinical Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 949 participants.

Also called NCT05809596

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 949 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05809596
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05809596. Allocation not applicable; no masking; primary purpose treatment. Start 2023-10-03 (actual); primary completion 2024-07-15 (actual). Results posted on 2025-10-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
HEAL-LAA Clinical Trial
Acronym
HEAL-LAA
Condition
Bleeding
Condition
Stroke
Intervention (Device)
WATCHMAN FLX Pro LAAC Device
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct05809596
Content hash
9b3568289b854ff5403e7313833e8a2d7316d1e34e9c18278faff04508e27a9c